Current disease status-Recurrent leukemia Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia in a real life setting

Posted by on Apr 24, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of idelalisib (Zydelig) and rituximab (Rituxan) in patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) in a real-life setting.  This study concluded that this treatment in a real-life setting was just as effective as in a clinical trial...

Read More

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Comparing nilotinib and dasatinib as second line treatment in patients with chronic myeloid leukemia in a real-life setting

Posted by on Apr 11, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare dasatinib (Sprycel) and nilotinib (Tasigna) as second-line treatments for patients with chronic-phase (CP) chronic myeloid leukemia (CML) in a real-life setting.   This study concluded that both dasatinib and nilotinib are equally effective and well...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.  This study concluded that this treatment path is feasible and a good alternative for these patients.   Some background Allogenic hemopoietic...

Read More

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Long-term outcomes of the combination of ibrutinib, bendamustine and rituximab in relapsed/unresponsive CLL/SLL

Posted by on Sep 24, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term effectiveness of the combination of ibrutinib, bendamustine, and rituximab in relapsed/unresponsive chronic lymphocytic leukemia/small lymphocytic lymphoma.  This study concluded that this combination was safe and effective in the long-term in these...

Read More

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia.   This study concluded that this treatment combination is safe and effective as a salvage treatment...

Read More

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Managing patients with chronic myeloid leukemia who fail responding to second generation tyrosine kinase inhibitors

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...

Read More

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Long-term outcomes for CAR-T cells treatment for relapsed or unresponsive chronic lymphocytic leukemia

Posted by on May 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia.  This study concluded that high-dose treatment may be more effective in these patients in the long term.   Some background Chimeric antigen...

Read More

The effects of blinatumomab in patients with relapsed or unresponsive acute lymphoblastic leukemia in outside of clinical trials

Posted by on Feb 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...

Read More